In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...

AstraZeneca (LSE: AZN) posted a robust second-quarter 2025 performance, lifted by record growth in its US business and solid ...

FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and ...

New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...

The Union Budget 2024, while significantly increasing health sector funding to ₹90,959 crore, failed to address the BJP’s ...

“I am delighted and relieved that osimertinib will now be offered as a first-line treatment to lung cancer patients with EGFR mutation-positive NSCLC,” he commented.

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Teliso-V ...

Researchers recommended that regulators consider mandating head-to-head trials comparing next-in-class and against existing in-class agents when possible.

Researchers at Tsinghua University have unveiled a new Python toolkit for automated single-cell lineage tracing and analysis—featuring rapid barcode QC, clone-size metrics, dynamic Sankey ...

AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, ...